Profile
Position
Ray Schrock, Global Chair of the Restructuring & Special Situations Practice, represents public and private companies, private equity sponsors, creditors, and other clients in complex liability management transactions and complex international and US restructuring matters.
Widely recognized as one of the world’s leading restructuring lawyers, ranked Band 1 by Chambers & Partners globally and in the United States, Ray advises leading public companies, financial institutions, private equity funds, portfolio companies, and creditors on matters across multiple sectors in complex liability management transactions and restructurings.
Ray has led some of the world’s most novel and complex liability management transactions and complex restructurings, including: Sears, J. Crew, Serta Simmons Bedding, AMC Entertainment, Steward Health Systems, PG&E, Air Methods, Southeastern Grocers, Tidewater, DiTech, A&P Supermarkets, Ally Bank/ResCap, and many others.
Before joining Latham, Ray was practice co-chair and global management committee member at another leading global law firm.
Content supplied by Latham & Watkins LLP
Testimonials
Collated independently by Legal 500 research team.
- 'Jeff Bjork is known widely for his restructuring work. He emphasizes the necessary commercial foundations of restructuring projects, while his knowledge and experience in negotiation and on legal matters are exceptional.'
Key clients
- 2U AIG Financial Products Attestor Capital Audacy Bank of Montreal (BMO) Barretts Minerals Cox Operating CPF - Canada Holdings Corp Deutsche Bank EPR Properties Farfetch Imerys JOANN JPMorgan Chase Bank Lenders to SmileDirectClub MOD Super Fast Pizza, Oaktree Capital Range Parent and RobertShaw US Holding Corp Russell Crumpler and Christopher Farmer, as joint liquidators of Three Arrows Capital Sorrento Therapeutics Spirit Realty Capital Starry Group Holdings Thai Union Investments The Carlyle Group The Church of Jesus Christ of Latter-day Saints, a Utah corporation sole Travelport Trinity Capital Investments Vital Pharmaceuticals

